Benny Barnhart, MD
Psychiatry · Wichita Falls, TXNPI 1871571075
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,045 of the $7,188 with a category attached, or 84.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$831
- AbbVie$707
- Teva Pharmaceuticals USA, Inc.$681
- Neurocrine Biosciences, Inc.$570
- Takeda Pharmaceuticals U.S.A., Inc.$443
- plus $3K from 26 others
Across 305 payments — averaging $7705.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$498K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$492K
- Axsome Therapeutics, Inc.$286K
- AbbVie$280K
- Boehringer Ingelheim$225K
- Janssen Research & Development, LLC$188K
- plus $382K from 10 others
What the payments were for
- Speaking & faculty fees$1,00014%
- Food & beverage$6,04584%
- Education$1432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,000
How this compares
$7,188 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 18 | $142,561 |
| AristadaAripiprazole Lauroxil | 13 | $42,774 |
| CaplytaLumateperone Tosylate | 20 | $34,578 |
| VraylarCariprazine Hcl | 19 | $27,207 |
| RexultiBrexpiprazole | 14 | $22,134 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $21,338 |
| BelsomraSuvorexant | 30 | $18,424 |
| TrintellixVortioxetine Hydrobromide | 15 | $16,863 |
| Lisdexamfetamine Dimesylate | 56 | $10,972 |
| Clozapine | 57 | $9,946 |
| Oxcarbazepine | 92 | $8,346 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $7,790 |
| Quetiapine Fumarate | 216 | $6,580 |
| Olanzapine | 89 | $5,811 |
| Alprazolam | 333 | $3,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $681 | $142,56118 claims |
| Alkermes, Inc.Aristada | $156 | $42,77413 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $292 | $34,57820 claims |
| AbbVieVraylar | $707 | $27,20719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $443 | $24,65337 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $831 | $22,13414 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $282 | $21,33813 claims |
| MerckBelsomra | $54 | $18,42430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Wichita Falls
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.